EuMentis has completed a Series A to fund development to an IND filing of an NMDA antagonist for ASD, and is conducting a Series B round to fund development of EM-221 through Phase 2. For more information, please contact Mark Tepper (CEO) at:firstname.lastname@example.org
Our unique synthetic approach has many possible applications. We are always looking to capitalize on our team’s talent and experience by acquiring new promising therapies or partnering with like-minded companies or inventors.
EuMentis Therapeutics Inc. Announces the First Closing of a Targeted $40M Series B Financing to Advance Novel Therapeutics to Treat Autism Spectrum Disorder, Tourette Syndrome and Traumatic Brain Injury.Download PDF
EuMentis Therapeutics Inc. Receives $3 Million Award from United States Department of Defense (DoD) to Advance its Novel NMDA Receptor Antagonist for Traumatic Brain Injury.Download PDF
EuMentis Therapeutics, Inc. (“EuMentis” or the “Company”), a clinical-stage pharmaceutical company developing neurocircuit-selective medicines to treat neurodevelopmental disorders, announced today that it will initiate a phase 2 clinical study of EM-221 for the treatment of Tourette Syndrome.Download PDF